Papers - FUJIHARA Kazuo
-
Early Treatment Initiation with Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I.
Front Neurol 22 ( 12 ) 608149 2021.2
-
Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Nakashima I.
J Neurol 2021.1
-
CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder.
Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M.
Heliyon 7 ( 1 ) e05899 - e05899 2021.1
-
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S, on behalf of the PREVENT Study Group.
Mult Scler Relat Disord ( 47 ) 102641 2021.1
-
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, Fujihara K, Aoki M.
Mult Scler Relat Disord 22 ( 49 ) 102750 2021.1
-
New therapies for neuromyelitis optica spectrum disorders.
Levy M, Fujihara K. Place J.
Lancet Neurol. 20 ( 1 ) 60 - 67 2021.1
-
Patterns of cortical grey matter thickness reduction in multiple sclerosis.
Fujimori, Fujihara K, Wattjes M, Nakashima I.
Brain Behav 27 e02050 2021.1
-
Treatment of MOG Antibody Associated Disorders: Results of an International Survey.
Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintz en RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A.
J Neurol 267 ( 12 ) 3565 - 3577 2020.12
-
Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
Akaishi T, Fujimori J, Takahashi T, Misu T, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M, Ishii T, Aoki M, Fujihara K, Nakashima I.
J Neuroimmunol 15 ( 349 ) 577431 2020.12
-
Distinctive lesions of bran MRI between MOG-antibody-associated and AQP4-antibody-associated diseases.
Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Fujimori J, Nakashima I, Fujihara K, Aoki M.
J Neurol Neurosurg Psychiatry 92 ( 6 ) 2020.12
-
Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.
Akaishi T, Takshita T, Himori N, Takahashi T, Misu T, Ogawa R, Kaneko K, Fujimori J, Abe M, Ishii T, Fujihara K, Aoki M, Nakazawa T, Nakashima I.
Front Neurol 2 ( 11 ) 932 2020.9
-
Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders.
Akaishi T、Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, Aoki M, Fujihara K, Nakashima I.
Sci Rep 17 ( 10(1) ) 13890 2020.8
-
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.
Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D; Mughal T, Yamamura T.
Neurol Neuroimmunol Neuroinflamm 20 ( 7(5) ) e841 2020.8
-
Measurements of corpus callosum index and fractional anisotropy of the corpus callosum with their cutoffs are useful to comprehend global brain volume loss in multiple sclerosis.
Fujimori J, MD, Uryu K, Fujihara K, Wattjes MP, Suzuki C, Nakashima I.
Mult Scler Relat Disord 8 ( 45 ) 102388 2020.7
-
Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis.
Akaishi T, Takahashi T, Fujihara K, Misu T, Nishiyama S, Takai Y, Fujimori J, Abe M, Ishii T, Aoki M, Nakashima I.
Mult Scler Relat Disord 7 ( 45 ) 102382 2020.7
-
Risk factors of attacks in neuromyelitis optica spectrum disorders.
Akaishi T, Takahashi T, Fujihara K, Misu T, Abe M, Ishii T, Aoki M, Nakashima I.
J Neuroimmunol 15 ( 343 ) 577236 2020.6
-
Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients.
Whittam DH, Cobo-Calvo A, Chiriboga ASL, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin R, Mathey G, Laplaud D, Thouvenot F, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett J, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Anu Jacob A.
Mult Scler Relat Disord 2 ( 44 ) 102251 2020.6
-
Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K. Cook L.
Curr Opin Neurol 33 ( 3 ) 300 - 308 2020.6
-
Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K, with the Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD.
Front Neurol 26 ( 11 ) 501 2020.6
-
Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
Akaishi T, Takahashi T, Fujihara K, Abe M, Ishii T, Aoki M, Nakashima I, Misu T, Mugikura S.
PLoS One 3 ( 15(4) ) e0231225 2020.4